Target family: 2B. Retinoid X receptors (type: nhr)
Target: Retinoid X receptor-&beta;

Ligand: AGN194204 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.44 pIC50
Reference (Journal): Enantioselective syntheses of potent retinoid X receptor ligands: differential biological activities of individual antipodes.
Published in: J Med Chem

Ligand: alitretinoin (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1999), EMA (2000)
Median affinity:  pIC50
Reference (Journal): Characterization of three RXR genes that mediate the action of 9-cis retinoic acid.
Published in: Genes Dev

Ligand: alitretinoin (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1999), EMA (2000)
Median affinity:  pIC50
Reference (Journal): 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha.
Published in: Nature

Ligand: alitretinoin (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1999), EMA (2000)
Median affinity:  pIC50
Reference (Journal): Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids.
Published in: Proc Natl Acad Sci USA

Ligand: alitretinoin (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1999), EMA (2000)
Median affinity:  pIC50
Reference (Journal): Activation of retinoid X receptors induces apoptosis in HL-60 cell lines.
Published in: Mol Cell Biol

Ligand: alitretinoin (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1999), EMA (2000)
Median affinity:  pIC50
Reference (Journal): 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor.
Published in: Cell

Ligand: alitretinoin (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1999), EMA (2000)
Median affinity:  pIC50
Reference (Journal): Activation of specific RXR heterodimers by an antagonist of RXR homodimers.
Published in: Nature

Ligand: bexarotene (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1999), EMA (2001)
Primary target: yes
Median affinity: 7.699999809265137 pIC50
Reference (Journal): Therapeutic applications for ligands of retinoid receptors.
Published in: Curr Pharm Des

Ligand: bexarotene (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1999), EMA (2001)
Primary target: yes
Median affinity: 7.699999809265137 pIC50
Reference (Journal): Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells.
Published in: J Med Chem

Ligand: bexarotene (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1999), EMA (2001)
Primary target: yes
Median affinity: 7.699999809265137 pIC50
Reference (Journal): Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.
Published in: J Med Chem

Ligand: compound 28 [Heitel et al., 2019] (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.510000228881836 pEC50
Reference (Journal): Computer-Assisted Discovery and Structural Optimization of a Novel Retinoid X Receptor Agonist Chemotype.
Published in: ACS Med Chem Lett

Ligand: LG100268 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Therapeutic applications for ligands of retinoid receptors.
Published in: Curr Pharm Des